Patients with NSCLC had a statistically higher proportion of HLA-DR and CD39 expression than patients with SCLC (respectively, 11.8 vs. 1.1, p < 0.0001, and 20.0 vs. 3.0, p < 0.0001) and a statistically lower proportion of CD184 expression than patients with SCLC (16.5 vs. 35.1%, p = 0.0085). This evidence concerns the gene ENTPD1 and non-small cell lung carcinoma.